Nektar Therapeutics Stock Prediction
AI-powered sentiment analysis and prediction trends for NKTR, updated each market day.
NKTR AI Sentiment
AI sees no strong directional signal for Nektar Therapeutics stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Sector
Exchange
Market Cap
$2,233,357,919
Cap Tier
Employees
63
Headquarters
SAN FRANCISCO, CA
Listed Since
May 3, 1994
Website
NKTR Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
NKTR Volatility
Nektar Therapeutics has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
